Your browser doesn't support javascript.
loading
Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study.
Bayle, A; Belcaid, L; Aldea, M; Vasseur, D; Peyraud, F; Nicotra, C; Geraud, A; Sakkal, M; Seknazi, L; Cerbone, L; Blanc-Durand, F; Hadoux, J; Mosele, F; Tagliamento, M; Bernard-Tessier, A; Verret, B; Smolenschi, C; Clodion, R; Auger, N; Romano, P M; Gazzah, A; Camus, M N; Micol, J; Caron, O; Hollebecque, A; Loriot, Y; Besse, B; Lacroix, L; Rouleau, E; Ponce, S; Soria, J C; Barlesi, F; Andre, F; Italiano, A.
Afiliación
  • Bayle A; Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif; Université Paris-Saclay, Faculté de médecine, Le Kremlin Bicêtre, Paris; Oncostat U1018, Inserm, Paris-Saclay University, labeled Ligue Contre le Cancer, Villejuif, France.
  • Belcaid L; Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif; Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Aldea M; Department of Cancer Medicine, Gustave Roussy, Villejuif.
  • Vasseur D; Department of Medical Biology and Pathology, Gustave Roussy, Villejuif.
  • Peyraud F; Department of Early Phase Trial Unit, Institut Bergonié Comprehensive Cancer Centre, Bordeaux.
  • Nicotra C; Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif.
  • Geraud A; Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif.
  • Sakkal M; Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif; Department of Cancer Medicine, Gustave Roussy, Villejuif.
  • Seknazi L; Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif.
  • Cerbone L; Department of Cancer Medicine, Gustave Roussy, Villejuif.
  • Blanc-Durand F; Department of Cancer Medicine, Gustave Roussy, Villejuif.
  • Hadoux J; Department of Cancer Medicine, Gustave Roussy, Villejuif.
  • Mosele F; Department of Cancer Medicine, Gustave Roussy, Villejuif.
  • Tagliamento M; Department of Cancer Medicine, Gustave Roussy, Villejuif.
  • Bernard-Tessier A; Department of Cancer Medicine, Gustave Roussy, Villejuif.
  • Verret B; Université Paris-Saclay, Faculté de médecine, Le Kremlin Bicêtre, Paris; Department of Cancer Medicine, Gustave Roussy, Villejuif.
  • Smolenschi C; Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif.
  • Clodion R; Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif.
  • Auger N; Department of Medical Biology and Pathology, Gustave Roussy, Villejuif.
  • Romano PM; Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif.
  • Gazzah A; Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif.
  • Camus MN; Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif.
  • Micol J; Department of Hematology, Gustave Roussy, Villejuif.
  • Caron O; Department of Genetics, Gustave Roussy, Villejuif.
  • Hollebecque A; Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif.
  • Loriot Y; Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif.
  • Besse B; Université Paris-Saclay, Faculté de médecine, Le Kremlin Bicêtre, Paris; Department of Cancer Medicine, Gustave Roussy, Villejuif.
  • Lacroix L; Department of Medical Biology and Pathology, Gustave Roussy, Villejuif.
  • Rouleau E; Department of Medical Biology and Pathology, Gustave Roussy, Villejuif.
  • Ponce S; Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif.
  • Soria JC; Université Paris-Saclay, Faculté de médecine, Le Kremlin Bicêtre, Paris; Department of Cancer Medicine, Gustave Roussy, Villejuif.
  • Barlesi F; Université Paris-Saclay, Faculté de médecine, Le Kremlin Bicêtre, Paris; Department of Cancer Medicine, Gustave Roussy, Villejuif.
  • Andre F; Université Paris-Saclay, Faculté de médecine, Le Kremlin Bicêtre, Paris; Department of Cancer Medicine, Gustave Roussy, Villejuif.
  • Italiano A; Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif; Department of Early Phase Trial Unit, Institut Bergonié Comprehensive Cancer Centre, Bordeaux; Faculty of Medicine, University of Bordeaux, Bordeaux, France. Electronic address: Antoine.italiano@gustaveroussy.fr.
Ann Oncol ; 34(4): 389-396, 2023 04.
Article en En | MEDLINE | ID: mdl-36709039
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: ADN Tumoral Circulante / Neoplasias Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: ADN Tumoral Circulante / Neoplasias Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido